Literature DB >> 26170322

Alleviation of off-target effects from vector-encoded shRNAs via codelivered RNA decoys.

Stefan Mockenhaupt1, Stefanie Grosse1, Daniel Rupp2, Ralf Bartenschlager2, Dirk Grimm3.   

Abstract

Exogenous RNAi triggers such as shRNAs ideally exert their activities exclusively via the antisense strand that binds and silences designated target mRNAs. However, in principle, the sense strand also possesses silencing capacity that may contribute to adverse RNAi side effects including off-target gene regulation. Here, we address this concern with a novel strategy that reduces sense strand activity of vector-encoded shRNAs via codelivery of inhibitory tough decoy (TuD) RNAs. Using various shRNAs for proof of concept, we validate that coexpression of TuDs can sequester and inactivate shRNA sense strands in human cells selectively without affecting desired antisense activities from the same shRNAs. Moreover, we show how coexpressed TuDs can alleviate shRNA-mediated perturbation of global gene expression by specifically de-repressing off-target transcripts carrying seed matches to the shRNA sense strand. Our combination of shRNA and TuD in a single bicistronic gene transfer vector derived from Adeno-associated virus (AAV) enables a wide range of applications, including gene therapies. To this end, we engineered our constructs in a modular fashion and identified simple hairpin design rules permitting adaptation to preexisting or new shRNAs. Finally, we demonstrate the power of our vectors for combinatorial RNAi strategies by showing robust suppression of hepatitis C virus (HCV) with an AAV expressing a bifunctional TuD against an anti-HCV shRNA sense strand and an HCV-related cellular miRNA. The data and tools reported here represent an important step toward the next generation of RNAi triggers with increased specificity and thus ultimately safety in humans.

Entities:  

Keywords:  AAV; Adeno-associated viral vector; RNA interference; off-targeting; short hairpin RNA

Mesh:

Substances:

Year:  2015        PMID: 26170322      PMCID: PMC4522753          DOI: 10.1073/pnas.1510476112

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  71 in total

1.  Rational design of therapeutic siRNAs: minimizing off-targeting potential to improve the safety of RNAi therapy for Huntington's disease.

Authors:  Ryan L Boudreau; Ryan M Spengler; Beverly L Davidson
Journal:  Mol Ther       Date:  2011-09-27       Impact factor: 11.454

2.  Widespread siRNA "off-target" transcript silencing mediated by seed region sequence complementarity.

Authors:  Aimee L Jackson; Julja Burchard; Janell Schelter; B Nelson Chau; Michele Cleary; Lee Lim; Peter S Linsley
Journal:  RNA       Date:  2006-05-08       Impact factor: 4.942

3.  Asymmetry in siRNA design.

Authors:  D Grimm
Journal:  Gene Ther       Date:  2009-04-30       Impact factor: 5.250

4.  Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans.

Authors:  A Fire; S Xu; M K Montgomery; S A Kostas; S E Driver; C C Mello
Journal:  Nature       Date:  1998-02-19       Impact factor: 49.962

5.  Molecular dissection of human Argonaute proteins by DNA shuffling.

Authors:  Nina Schürmann; Leonardo G Trabuco; Christian Bender; Robert B Russell; Dirk Grimm
Journal:  Nat Struct Mol Biol       Date:  2013-06-09       Impact factor: 15.369

6.  Positional effects and strand preference of RNA interference against hepatitis C virus target sequences.

Authors:  R M Smith; R Smolic; M Volarevic; G Y Wu
Journal:  J Viral Hepat       Date:  2007-03       Impact factor: 3.728

7.  Minimizing variables among hairpin-based RNAi vectors reveals the potency of shRNAs.

Authors:  Ryan L Boudreau; Alex Mas Monteys; Beverly L Davidson
Journal:  RNA       Date:  2008-08-12       Impact factor: 4.942

8.  Low-level shRNA cytotoxicity can contribute to MYC-induced hepatocellular carcinoma in adult mice.

Authors:  Shelly Beer; David I Bellovin; Joyce S Lee; Kimberly Komatsubara; Lora S Wang; Huishan Koh; Kathleen Börner; Theresa A Storm; Corrine R Davis; Mark A Kay; Dean W Felsher; Dirk Grimm
Journal:  Mol Ther       Date:  2009-10-20       Impact factor: 11.454

9.  The effects of stem length and core placement on shRNA activity.

Authors:  Glen J McIntyre; Yi-Hsin Yu; Mehnaaz Lomas; Gregory C Fanning
Journal:  BMC Mol Biol       Date:  2011-08-08       Impact factor: 2.946

10.  The anti-genomic (negative) strand of Hepatitis C Virus is not targetable by shRNA.

Authors:  Leszek Lisowski; Menashe Elazar; Kirk Chu; Jeffrey S Glenn; Mark A Kay
Journal:  Nucleic Acids Res       Date:  2013-02-08       Impact factor: 16.971

View more
  20 in total

1.  Future of rAAV Gene Therapy: Platform for RNAi, Gene Editing, and Beyond.

Authors:  Paul N Valdmanis; Mark A Kay
Journal:  Hum Gene Ther       Date:  2017-01-10       Impact factor: 5.695

2.  Effective and Accurate Gene Silencing by a Recombinant AAV-Compatible MicroRNA Scaffold.

Authors:  Jun Xie; Phillip W L Tai; Alexander Brown; Shoufang Gong; Sha Zhu; Yi Wang; Chengjian Li; Cansu Colpan; Qin Su; Ran He; Hong Ma; Jia Li; Hanqing Ye; Jihye Ko; Phillip D Zamore; Guangping Gao
Journal:  Mol Ther       Date:  2019-11-27       Impact factor: 11.454

3.  ABCB1 Mediates Cabazitaxel-Docetaxel Cross-Resistance in Advanced Prostate Cancer.

Authors:  Alan P Lombard; Chengfei Liu; Cameron M Armstrong; Vito Cucchiara; Xinwei Gu; Wei Lou; Christopher P Evans; Allen C Gao
Journal:  Mol Cancer Ther       Date:  2017-07-11       Impact factor: 6.261

Review 4.  Guidelines for the optimal design of miRNA-based shRNAs.

Authors:  Xavier Bofill-De Ros; Shuo Gu
Journal:  Methods       Date:  2016-04-12       Impact factor: 3.608

Review 5.  From Loci to Biology: Functional Genomics of Genome-Wide Association for Coronary Disease.

Authors:  Sylvia T Nurnberg; Hanrui Zhang; Nicholas J Hand; Robert C Bauer; Danish Saleheen; Muredach P Reilly; Daniel J Rader
Journal:  Circ Res       Date:  2016-02-19       Impact factor: 17.367

6.  Blocking sense-strand activity improves potency, safety and specificity of anti-hepatitis B virus short hairpin RNA.

Authors:  Thomas Michler; Stefanie Große; Stefan Mockenhaupt; Natalie Röder; Ferdinand Stückler; Bettina Knapp; Chunkyu Ko; Mathias Heikenwalder; Ulrike Protzer; Dirk Grimm
Journal:  EMBO Mol Med       Date:  2016-09-01       Impact factor: 12.137

7.  Off Target, but Sequence-Specific, shRNA-Associated Trans-Activation of Promoter Reporters in Transient Transfection Assays.

Authors:  Tomohiro Masuda; Jun Wan; Anitha Yerrabelli; Cindy Berlinicke; Alyssa Kallman; Jiang Qian; Donald J Zack
Journal:  PLoS One       Date:  2016-12-15       Impact factor: 3.240

Review 8.  RNAi mechanisms in Huntington's disease therapy: siRNA versus shRNA.

Authors:  Sebastian Aguiar; Bram van der Gaag; Francesco Albert Bosco Cortese
Journal:  Transl Neurodegener       Date:  2017-11-27       Impact factor: 8.014

9.  TALEN/CRISPR-mediated engineering of a promoterless anti-viral RNAi hairpin into an endogenous miRNA locus.

Authors:  Elena Senís; Stefan Mockenhaupt; Daniel Rupp; Tobias Bauer; Nagarajan Paramasivam; Bettina Knapp; Jan Gronych; Stefanie Grosse; Marc P Windisch; Florian Schmidt; Fabian J Theis; Roland Eils; Peter Lichter; Matthias Schlesner; Ralf Bartenschlager; Dirk Grimm
Journal:  Nucleic Acids Res       Date:  2016-09-09       Impact factor: 16.971

Review 10.  In vivo genome editing in animals using AAV-CRISPR system: applications to translational research of human disease.

Authors:  Cia-Hin Lau; Yousin Suh
Journal:  F1000Res       Date:  2017-12-20
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.